| Literature DB >> 25647086 |
Hui Yu1, Qi Wang2, Ying Sun2, Ming Shen2, He Li3, Yourong Duan2.
Abstract
The purpose of this work was to investigate the synthetic phospholipid dependence of permeability measured by parallel artificial membrane permeability assay (PAMPA) method. Three phospholipids with hydrophobic groups of different lengths and phosphorylcholine as the hydrophilic group were concisely synthesized. Ten model drug molecules were selected because of their distinct human fraction absorbed (%FA) values and various pKa characteristics. In vitro drug permeation experiments were designed to determine the effect of the incubation time (4-20 h), pH gradient (4.6-9.32) and carbon chain length (8, 10, 12) on the drug permeability through the synthetic phospholipid membrane in the PAMPA system. The results showed that intensive and significant synthetic phospholipids dependence of permeability influenced by the length of lipid's hydrophobic carbon chain. The effective permeability constant (Pe) of each drug increased rapidly with time, then decreased slightly after reaching the maximum; the pH gradient changed the drug permeability according to the pH-partition hypothesis for drugs with diverse pKa values; and longer hydrophobic chains in the synthetic phospholipid membrane improved the drug permeability, as observed for all test drugs at almost all incubation time points. This newly proposed PAMPA model considered the synthetic phospholipid membrane and showed good Pe-%FA correlation for the passive transport of drugs, making it a helpful supplementary method for PAMPA systems.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25647086 PMCID: PMC4315410 DOI: 10.1371/journal.pone.0116502
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Synthetic scheme for the phospholipids.
Fig 2Schematic of the PAMPA model.
The physical properties and permeability characteristic of model drugs.
| Compound | Molecular formula | Mw | Water solubility (mg/)a | p | %FAc |
| ||
|---|---|---|---|---|---|---|---|---|
| C8 | C10 | C12 | ||||||
| Amoxicillin | C16H25N3O8S | 419.46 | 3430 | 2.6, 7.31, 9.53 | 93 | 4.6±0.4 | 5.3±0.3 | 5.7±0.4 |
| Atenolol | C14H22N2O3 | 266.39 | 1.33×104 | 9.54 | 54 | 3.8±0.4 | 5.2±0.4 | 5.9±0.5 |
| Chloroamphenicol | C11H12Cl2N2O5 | 323.13 | 2500 | 4.3 | 90 | 8.8±0.2 | 9.8±0.3 | 14.6±0.3 |
| Cimetidine | C10H16N6S | 252.34 | 9380 | 7.23 | 85 | 2.6±0.4 | 2.8±0.3 | 3.2±0.3 |
| Famotidine | C8H15N7O2S3 | 337.45 | 1000 | 7.24, 11.19 | 40 | 2.7±0.3 | 2.8±0.2 | 3.2±0.4 |
| Ibuprofen | C13H18O2 | 206.28 | 21 | 4.59 | 95 | 13.9±0.5 | 14.5±0.5 | 16.7±0.4 |
| Metformin Hydrochloride | C4H11N5·HCl | 165.63 | Freely soluble | 12.4 | 55 | 2.4±0.4 | 2.9±0.3 | 3.4±0.2 |
| Metoprolol Tartrate | (C15H25NO3)2·C4H6O6 | 682.82 | 1.69×104 | 9.56 | 95 | 9.2±0.6 | 10.3±0.5 | 11.7±0.5 |
| Norfloxacin | C15H18N3O3F | 319.34 | 1.78×105 | 6.26, 8.63 | 35 | 0.9±0.1 | 1.0±0.1 | 1.0±0.1 |
| Ranitidine | C13H24N4O3S· | 314.37 | 24.7 | 8.2 | 55 | 1.2±0.1 | 1.4±0.1 | 1.5±0.1 |
a Data come from DrugBank database
b Data collected from Chinese Pharmacopoeia, 2005 edition and references [15,27,38]
c %FA data obtained from references [16,40]
d Incubation time is 16h
Fig 3The measured P e vs. permeation time for drugs at pH 7.4.
The error bars were determined from 3 replicate measurements. Squares denote the phospholipids with octyl chains (C8) as the hydrophobic group; dots denote the phospholipids with decyl (C10) chains as the hydrophobic group0; triangles denote the phospholipids with lauryl (C12) chains as the hydrophobic group.
Fig 4The measured P e vs. various pH gradients; the error bars were determined from 3 replicates.
Squares denote C8, dots denote C10, and triangles denote C12.
pH-P e experimental data.
| Compounds | pH |
| |||||
|---|---|---|---|---|---|---|---|
| C8 | S.D. | C10 | S.D. | C12 | S.D. | ||
| Amoxicillin (×10–7) | 4.6 | 1.9 | 0.2 | 1.9 | 0.2 | 1.9 | 0.2 |
| 4.98 | 2.1 | 0.2 | 2.1 | 0.1 | 2.1 | 0.1 | |
| 6.57 | 2.6 | 0.2 | 2.5 | 0.2 | 2.6 | 0.2 | |
| 8.2 | 2.4 | 0.2 | 2.3 | 0.2 | 2.3 | 0.2 | |
| 9.32 | 2.2 | 0.2 | 2.2 | 0.2 | 2.0 | 0.2 | |
| Atenolol (×10–6) | 4.6 | – | – | – | – | – | – |
| 4.98 | 2.5 | 0.4 | 1.7 | 0.1 | 1.5 | 0.1 | |
| 6.57 | 3.0 | 0.5 | 3.2 | 0.2 | 3.3 | 0.4 | |
| 8.2 | 3.8 | 0.4 | 3.5 | 0.4 | 3.5 | 0.2 | |
| 9.32 | 4.4 | 0.1 | 4.4 | 0.3 | 4.4 | 0.5 | |
| Chloroamphenicol (×10–6) | 4.6 | 4.3 | 0.4 | 4.2 | 0.5 | 4.4 | 0.4 |
| 4.98 | 4.2 | 0.5 | 4 | 0.3 | 4.2 | 0.6 | |
| 6.57 | 1.7 | 0.4 | 1 | 0.2 | 1.5 | 0.4 | |
| 8.2 | 0.6 | 0.1 | 0.7 | 0.1 | 0.7 | 0.1 | |
| 9.32 | 0.5 | 0.1 | 0.5 | 0.1 | 0.5 | 0.1 | |
| Cimetidine (×10–6) | 4.6 | 1.8 | 0.3 | 1.8 | 0.3 | 1.8 | 0.4 |
| 4.98 | 1.6 | 0.2 | 1.9 | 0.1 | 1.9 | 0.3 | |
| 6.57 | 2.6 | 0.1 | 2.6 | 0.2 | 2.7 | 0.2 | |
| 8.2 | 3.2 | 0.2 | 3.1 | 0.3 | 3.2 | 0.2 | |
| 9.32 | 3.7 | 0.2 | 3.4 | 0.3 | 3.4 | 0.1 | |
| Famotide (×10–6) | 4.6 | 1.1 | 0.2 | 1.2 | 0.2 | 1.2 | 0.2 |
| 4.98 | 2.2 | 0.1 | 2.2 | 0.1 | 1.2 | 0.1 | |
| 6.57 | 5.0 | 0.4 | 5.7 | 0.4 | 6.0 | 0.1 | |
| 8.2 | – | – | – | – | – | – | |
| 9.32 | 5.1 | 0.2 | 5.5 | 0.1 | 6.1 | 0.2 | |
| Ibuprofen (×10–6) | 4.6 | 23.0 | 1.5 | 23.0 | 1.0 | 22.5 | 2.0 |
| 4.98 | 23.5 | 2.0 | 22.0 | 2.0 | 23.0 | 2.5 | |
| 6.57 | 8.5 | 0.2 | 7.0 | 0.1 | 7.5 | 0.2 | |
| 8.2 | 3.0 | 0.1 | 1.5 | 0.1 | 1.5 | 0.1 | |
| 9.32 | 2.6 | 0.1 | 2.6 | 0.1 | 2.6 | 0.1 | |
| Metformin Hydrochloride (×10–7) | 4.6 | 1.5 | 0.1 | 1.5 | 0.2 | 1.6 | 0.2 |
| 4.98 | 1.6 | 0.1 | 1.6 | 0.1 | 1.7 | 0.2 | |
| 6.57 | 3.2 | 0.1 | 3.2 | 0.2 | 3.1 | 0.1 | |
| 8.2 | 4.9 | 0.1 | 5.8 | 0.2 | 4.9 | 0.1 | |
| 9.32 | 7.4 | 0.1 | 7.2 | 0.2 | 7.3 | 0.1 | |
| Metoprolol Tartrate (×10–5) | 4.6 | 1.5 | 0.1 | 1.4 | 0.2 | 1.6 | 0.2 |
| 4.98 | 2.7 | 0.2 | 2.5 | 0.2 | 2.6 | 0.2 | |
| 6.57 | 5.1 | 0.3 | 5.3 | 0.3 | 5.0 | 0.2 | |
| 8.2 | 8.0 | 0.1 | 7.5 | 0.3 | 8.0 | 0.4 | |
| 9.32 | 8.9 | 0.2 | 9.3 | 0.3 | 9.1 | 0.3 | |
| Norfloxacin (×10–6) | 4.6 | 1.9 | 0.0 | 1.9 | 0.1 | 1.8 | 0.1 |
| 4.98 | 2.3 | 0.1 | 2.2 | 0.1 | 2.2 | 0.1 | |
| 6.57 | 2.6 | 0.0 | 2.5 | 0.1 | 2.6 | 0.0 | |
| 8.2 | 2.5 | 0.1 | 2.5 | 0.1 | 2.6 | 0.1 | |
| 9.32 | 2.2 | 0.1 | 2.3 | 0.1 | 2.2 | 0.1 | |
| Ranitidine (×10–7) | 4.6 | 1.6 | 0.1 | 1.6 | 0.3 | 1.6 | 0.2 |
| 4.98 | 1.8 | 0.2 | 1.8 | 0.2 | 1.8 | 0.2 | |
| 6.57 | 3.2 | 0.1 | 3.1 | 0.1 | 3.2 | 0.2 | |
| 8.2 | 4.9 | 0.1 | 5.8 | 0.7 | 4.9 | 0.2 | |
| 9.32 | 5.5 | 0.2 | 5.5 | 0.3 | 5.4 | 0.4 | |